1. The immunosuppressive footprint of CLL on nonmalignant lymphocytes is more pronounced in the lymph node microenvironment.
2. Venetoclax combination treatment reduces immunosuppressive features of CLL, suggesting immune recovery after elimination of tumor cells.
Understanding the effects of novel treatment regimens on the immune system is particularly important considering the fact that infections remain a leading cause of morbidity and mortality in CLL.35,36 In addition, knowledge about how venetoclax impacts lymphocytes may be valuable in designing future combination strategies and shed light on possible risks associated with long-term treatment. Eradication of the malignant clone potentially allows recovery of immune responses and, thus, immunosurveillance.